A tri-specific killer engager against mesothelin targets NK cells towards lung cancer.
NK cell
NSCLC
TriKE
biologic
cancer
immunotherapy
lung
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
03
10
2022
accepted:
06
02
2023
entrez:
13
3
2023
pubmed:
14
3
2023
medline:
15
3
2023
Statut:
epublish
Résumé
New treatments are required to enhance current therapies for lung cancer. Mesothelin is a surface protein overexpressed in non-small cell lung cancer (NSCLC) that shows promise as an immunotherapeutic target in phase I clinical trials. However, the immunosuppressive environment in NSCLC may limit efficacy of these therapies. We applied time-of-flight mass cytometry to examine the state of circulating mononuclear cells in fourteen patients undergoing treatment for unresectable lung cancer. Six patients had earlier stage NSCLC (I-IVA) and eight had highly advanced NSCLC (IVB). The advanced NSCLC patients relapsed with greater frequency than the earlier stage patients. Before treatment, patients with very advanced NSCLC had a greater proportion of CD14
Identifiants
pubmed: 36911670
doi: 10.3389/fimmu.2023.1060905
pmc: PMC9992642
doi:
Substances chimiques
Mesothelin
J27WDC343N
Immunosuppressive Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1060905Informations de copyright
Copyright © 2023 Kennedy, Vallera, Ettestad, Hallstrom, Kodal, Todhunter, Bendzick, Hinderlie, Walker, Pulkrabek, Pastan, Kratzke, Fujioka, Miller and Felices.
Déclaration de conflit d'intérêts
NF served on the advisory board for Takeda in 2020 and 2021 and the advisory board for Astra Zeneca in 2020. Neither Takeda nor Astra Zeneca provided any funding for the work herein. DV, JM and MF receive research support and, with the University of Minnesota, are shared owners of the TriKE technology licensed by the University to GT Biopharma Inc. In addition, JM and MF consult for and hold stock options in GT BioPharma Inc. These interests have been reviewed and managed by the University of Minnesota in accordance with its conflict of interest policy. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Tumour Biol. 2016 Apr;37(4):5285-93
pubmed: 26561466
Oncotarget. 2015 May 10;6(13):11694-703
pubmed: 26028668
Nat Biotechnol. 1999 Jun;17(6):568-72
pubmed: 10385321
J Clin Oncol. 2015 Jan 1;33(1):74-82
pubmed: 25403209
Clin Cancer Res. 2005 Aug 15;11(16):5840-6
pubmed: 16115924
Cancer Discov. 2016 Feb;6(2):133-46
pubmed: 26503962
Cell. 2017 May 4;169(4):750-765.e17
pubmed: 28475900
Cancer Immunol Res. 2017 Jan;5(1):3-8
pubmed: 28052991
Am J Surg Pathol. 2003 Nov;27(11):1418-28
pubmed: 14576474
Blood. 2018 Jun 7;131(23):2515-2527
pubmed: 29463563
Methods Mol Biol. 2016;1441:333-46
pubmed: 27177679
Cell. 2019 Jun 13;177(7):1701-1713.e16
pubmed: 31155232
Clin Cancer Res. 2018 Nov 15;24(22):5552-5561
pubmed: 30045932
Clin Cancer Res. 2007 Mar 1;13(5):1571-5
pubmed: 17332303
Cancers (Basel). 2020 Sep 18;12(9):
pubmed: 32961861
Lancet Oncol. 2018 May;19(5):694-704
pubmed: 29628312
Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):669-74
pubmed: 9435250
Nat Rev Clin Oncol. 2021 Oct;18(10):625-644
pubmed: 34168333
J Leukoc Biol. 2015 Apr;97(4):761-7
pubmed: 25713086
Am J Surg Pathol. 2003 Feb;27(2):150-8
pubmed: 12548160
N Engl J Med. 2020 Aug 13;383(7):640-649
pubmed: 32786189
JAMA Oncol. 2018 Mar 01;4(3):351-357
pubmed: 29327044
Mol Cancer Ther. 2002 Jun;1(8):595-600
pubmed: 12479219
Am J Surg Pathol. 1992 Mar;16(3):259-68
pubmed: 1599018
Clin Cancer Res. 2016 Jul 15;22(14):3440-50
pubmed: 26847056
J Clin Oncol. 2016 Dec;34(34):4171-4179
pubmed: 27863199
Stem Cell Res Ther. 2022 Apr 12;13(1):165
pubmed: 35414042
Clin Exp Immunol. 2019 Feb;195(2):179-189
pubmed: 30246868
Cancers (Basel). 2021 Aug 08;13(16):
pubmed: 34439149
J Thorac Oncol. 2015 Feb;10(2):280-5
pubmed: 25299234
Blood Adv. 2019 Jul 9;3(13):1970-1980
pubmed: 31266741
Biochemistry. 1994 May 10;33(18):5451-9
pubmed: 7910034
Immunol Cell Biol. 2014 Mar;92(3):245-55
pubmed: 24445602
Mol Ther. 2019 Nov 6;27(11):1919-1929
pubmed: 31420241
J Clin Oncol. 2021 Mar 1;39(7):723-733
pubmed: 33449799
Oncotarget. 2019 Dec 24;10(67):7142-7155
pubmed: 31903172
Onco Targets Ther. 2016 Aug 08;9:4879-86
pubmed: 27540301
Cancer Immunol Res. 2020 Sep;8(9):1139-1149
pubmed: 32661096
Immunotherapy. 2018 Jun;10(8):681-694
pubmed: 29882691
Immunol Lett. 2017 Oct;190:159-168
pubmed: 28823521
Nat Rev Immunol. 2018 Nov;18(11):671-688
pubmed: 30209347
Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419839592
pubmed: 30968711
Biomark Res. 2019 Aug 23;7:18
pubmed: 31463062
Clin Cancer Res. 2014 Feb 15;20(4):1020-8
pubmed: 24334761
Target Oncol. 2020 Apr;15(2):241-247
pubmed: 32285316
Lung Cancer. 2019 Jan;127:153-163
pubmed: 30642544
J Immunother Cancer. 2022 Sep;10(9):
pubmed: 36162918
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Front Immunol. 2019 Jul 10;10:1593
pubmed: 31354732
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40
pubmed: 8552591
Oncotarget. 2018 May 15;9(37):24801-24820
pubmed: 29872507
Blood Adv. 2018 Jun 26;2(12):1459-1469
pubmed: 29941459
BMJ. 2022 Mar 30;376:e069008
pubmed: 35354556
Oncoimmunology. 2016 May 13;6(1):e1163456
pubmed: 28197362
Control Clin Trials. 1998 Dec;19(6):589-601
pubmed: 9875838